Q1 FY 2027 Investor Presentation

August 10, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block, Bandra Kurla Complex, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 SCRIP CODE: 543748 SYMBOL: AARTIPHARM Dear Sir/Madam, Sub: Results Presentation Ref: Regulation 30 of the SEBI (LODR) Regulations 2015 Please find enclosed herewith the Q1 FY27 Results Presentation of the Company for your records. The same is also being uploaded on Company’s website https://www.aartipharmalabs.com/ presentation Please take the same on your records. Thanking you, Yours faithfully, For AARTI PHARMALABS LIMITED JEEVAN MONDKAR COMPANY SECRETARY AND LEGAL HEAD ICSI M. NO. A22565 Encl. a/a. INVESTOR PRESENTATION August 2026 SNAPSHOT 25+ Years of Pharmaceutical Excellence 220+ 500+ Products Global Clients State-of-the-art R&D facilities 63 50+ Patents Filed Export Countries Manufacturing 60 US DMF Units 2,400+ Employees 3 44 USFDA Units CEP Global 15-20% Market Share 0.32x Credit rating Net Debt/Equity in Xanthine Aarti Pharmalabs Limited COMPANY BUSINESS STRATEGIC FINANCIAL OVERVIEW OVERVIEW OVERVIEW OVERVIEW Aarti Pharmalabs Limited COMPANY OVERVIEW STANDALONE REVENUE (INR Mn) • Aarti Pharmalabs Limited (APL) is part of the Aarti group – a diversified chemical conglomerate with & EBITDA MARGINS (%) group turnover of INR 145+ bn (FY26) 17,714 17,976 • Globally recognized manufacturer of generic API, Xanthine derivatives (Worlds third largest capacity) 15,021 and a leading player in CDMO/CMO services • Demonstrated strong expertise in development of robust & cost-effective process for rapid scale up and commercial production 25% 19% 24% 5,346 • Received accreditation from several agencies, including USFDA, EU GMP, EDQM (European Pharmacopoeia), KFDA (Korea), and COFEPRIS (Mexico) • Strategically located in western India with proximity to ports FY24 FY25 FY26 Q1-FY26 GEOGRAPHICAL SALES (Q1-FY27) HIGHLIGHTS One of the leading small Regulatory focussed Largest manufacturer of Domestic, molecule CDMO/CMO operations with expertise in Xanthine Derivatives in 40% company in India. novel chemistries; India International, Aarti Pharmalabs Limited KEY MILESTONES 2026 • Inaugurated Tarapur(Unit 5), adding 3,600 TPA to reach a total capacity of 9,600 TPA 2024 • Started 21 MW solar power project at Akola, Maharashtra • Expansion of semi-commercial production block at Vapi 2022 • Expanded block for CSD in Vapi and API in Tarapur units 2025 • Acquired land at Atali for future growth • Successfully demerged the pharmaceutical business of Aarti Industries Limited to Aarti Pharmalabs Limited 11 Commissioned Phase 1 at Atali greenfield site with 450+ kL reactor capacity 2016 2023 Commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tons (MT) per month 9 • Operationalized the third R&D center • Secured USFDA approval for Dombivli Unit 8 • Commercialized Block V at Tarapur Unit 4 2009 • Enhanced Xanthine capacity to 5,000 TPA 2019 Successfully completed the USFDA audit at the Intermediate 7 facility (CSD) in Vapi Successfully completed an audit by EDQM for Bicalutamide for the Oncology block at Unit 4 2005 6 2013 Commissioned the first API manufacturing unit in Tarapur for Regulated Markets (Unit 4) Received EUGMP approval for Bicalutamide for the Oncology block at Unit 4 1984 2008 Aarti Organic Private Limited was incorporated Successfully completed the USFDA & EUGMP audit for Tarapur Unit 4 2001 Commissioned the first API manufacturing unit in Dombivli (Unit 1) and started the Xanthine unit Aarti Pharmalabs Limited GEOGRAPHICAL PRESENCE Atali Vapi - Unit II Tarapur - Unit III, IV, V, VI Dombivli - Unit I Gujarat Mumbai Maharashtra LOCATION MANUFACTURING UNITS CERTIFICATIONS & AUDIT DATE Dombivali Unit -I (API, Intermediates, CDMO) USFDA -Jun 2022 Unit -II (API, Intermediates, CDMO) Vapi USFDA -Sep 2009, Aug 2017 Custom Synthesis Division Unit –III (Xanthine Unit) USFDA –Mar 2008, Sep 2011, Mar 2015, Dec 2016, Feb 2020 EUGMP –Apr 2008, May 2012, Unit –IV (API, CDMO-API) Aug 2013, Jan 2015 HEAD OFFICE EDQM –Sep 2019, Tarapur KFDA –Nov 2017, R&D CENTER COFEPRIS –Apr 2017, May 2017 Unit -V (Xanthine Unit) Unit -VI (Intermediate unit of MANUFACTURING UNIT Xanthine, speciality & allied products) Atali AtaliUnit (Intermediates, CDMO) Aarti Pharmalabs Limited MANUFACTURING CAPABILITIES END TO END CAPABILITIES UNDER ONE UMBRELLA Hydrogenation facilities from lab-scale to 25+ years of experience in pharmaceuticals manufacturing scale (0.1-10 KL reactors) manufacturing for global clients Impeccable regulatory track record and facilities Cryogenic reactors operating within a approved by several pharmaceutical clients temperature range of -100°C to +150°C from EHS and Quality perspectives CAPABILITIES Continuous manufacturing, flow Dedicated Cyanation Manufacturing Block chemistry & bio-catalysis reaction Strong expertise in development of robust and HPAPI (Cytotoxic/Oncology) and Cortico cost-effective processes for rapid scale-up and Steroids development and manufacturing commercial production TECHNICAL CAPABILITIES MANUFACTURING CAPABILITIES Aarti Pharmalabs Limited RESEARCH & DEVELOPMENT 3 40+ 730+ State of the art Products developed and R&D Centers at manufactured on kilo-lab Maharashtra & Gujarat scale in FY25 25+ 7.4% 21 730+ 3 New products R&D Spend (as a PhDs launched at plant scale percent of API+Int & in FY25 CDMO sales) in FY26 122 3 65 Cr 730+ 61 730+ APIs commercialized R&D Process Scientists R&D Spend in FY26 63 31 730+ 730+ Process Patents Filed Patents Granted Aarti Pharmalabs Limited COMPANY BUSINESS STRATEGIC FINANCIAL OVERVIEW OVERVIEW OVERVIEW OVERVIEW Aarti Pharmalabs Limited XANTHINE DERIVATIVES & ALLIED PRODUCTS • World's third-largest and India's largest manufacturer of Xanthine Derivatives, including Caffeine SALES QUANTITY SPLIT (Q1-27) (largest capacity in India), Theophylline Anhydrous, Aminophylline, Etophylline, and Theophylline. • Non-Chinese dependent and fully backward integrated manufacturer of Xanthine derivatives, offering strong geographical diversification amidst “China+1” shift. Others, 26% • Two dedicated plants at Tarapur, Maharashtra with a combined capacity of 9,600+ MTPA for producing Xanthine Derivatives. • Capacity expanded from 5000 MTPA to 9,600+ MTPA, with phased ramp-up underway till FY27 end. Beverages, 74% • Expanded capacity is expected to drive global market share from 15–20% to 20–25%. GEOGRAPHICAL SALES SPLIT (Q1-FY27) END USE CERTIFICATIONS Domestic International Cola Drinks Energy Drinks Pharmaceutical Nutraceutical Aarti Pharmalabs Limited API & INTERMEDIATES • Specialized player in the development and manufacturing of HPAPIs, catering to the demand for critical drugs used in oncology, corticosteroids, and cytotoxic medicines. MARKET SEGMENTATION (Q1-FY27) • Backward integrated for most APIs, with control over entire production value chain and ensuring high-quality intermediates. • With USFDA approved manufacturing facilities and dedicated US, EU and Japan approvals, APL enjoys a distinct advantage over competition Regulated • Preferred partner in regulated markets driven by robust regulatory documentation and IPR support Non Regulated • 1,500+ KL multipurpose reactor capacity (fungible) and 14 API finished lines KEY HIGHLIGHTS THERAPEUTIC SEGMENT APIs Commercialized GEOGRAPHICAL SALES SPLIT (Q1-FY27) 11 New APIs under development CARDIOVASCULAR ANTI ASTHAMATIC ANTI CANCER ONCOLOGY (R&D / validation) International US DMF Approvals Domestic52% SKIN CARE OVERACTIVE BLADDER ANTI DIABETIC CNS AGENT CEP Approvals 140+ Intermediates CALCIMIMETIC DECONGESTANT ANTI THALASSAEMIC ANALGESIC 11 Aarti Pharmalabs Limited CDMO & CMO • Amongst leading small molecule CDMO/CMO players in India, working with big pharma, innovators CDMO Sales (INR Cr) and biotech companies. • Offering end to end services including proc [Showing first 8,000 characters — download PDF for full document]